drugset / Trial / NCT05155917

Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care

NCT05155917

Phase 2 Unknown 70 enrolled Changhua Christian Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

The safety and efficacy of basal insulin during intravenous insulin infusion for hyperglycemic crisis patients under critical care is still unknown. We assumed that concurrent basal insulin subcutaneous injection and intravenous insulin infusion for critically ill DKA and HHS patients would shorten the time of hyperglycemic crisis correction and achieved better glycemic control(decrease hypoglycemia and rebound hyperglycemia).

Timeline

Start
2022-03-01
Primary completion
2024-01
Completion
2024-01

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin glargine Protein / enzyme biologic 0.25 iu/kg Subcutaneous